Details:

Alternative Title:
Prev Chronic Dis
Publisher's site:
http://dx.doi.org/10.5888/pcd19.210228|10.1016/j.jare.2020.03.005|10.1111/all.14657|10.1016/j.cmi.2020.07.024|10.1038/s41598-021-82721-3|10.1136/gutjnl-2020-322118|10.1002/hep4.1648|10.1136/bmj.m1091|10.1136/bmj.n71|10.1097/XEB.0000000000000141|10.1002/hep.31649|10.3350/cmh.2020.0126|10.1016/j.livres.2021.01.001|10.1016/j.jhep.2020.03.044|10.1016/j.jhep.2021.04.052|10.1016/j.jinf.2020.03.019|10.18632/aging.103632|10.1186/s12876-021-02017-8|10.1111/liv.14575|10.1183/13993003.00547-2020|10.1016/j.ijantimicag.2020.106249|10.1016/j.jaut.2020.102473|10.1097/MEG.0000000000001968|10.1016/j.jamda.2021.01.070|10.1007/s13577-021-00499-y|10.1371/journal.pmed.1003321|10.1111/jgh.15112|10.1016/S0140-6736(20)30183-5|10.1016/j.cgh.2020.09.027|10.1016/S2213-2600(20)30579-8|10.1002/hep.31301|10.1007/s12072-020-10072-8|10.1136/gutjnl-2020-321611|10.1056/NEJMoa2002032|10.1016/j.jhep.2020.09.006|10.1053/j.gastro.2020.04.064|10.1016/j.eclinm.2020.100688|10.3748/wjg.v27.i42.7362|10.1053/j.gastro.2021.07.010|10.1111/liv.14583|10.1097/MEG.0000000000001902|10.1186/s40001-020-00454-x|10.1016/j.aohep.2020.10.001|10.1136/gutjnl-2020-322072|10.1097/MEG.0000000000001742|10.3389/fmed.2021.626425|10.1016/j.dld.2020.09.007|10.1007/s42399-020-00631-3|10.1097/PRS.0b013e3181f44abc|10.1101/2020.06.04.20122457|10.1136/gutjnl-2020-321611|10.1016/j.jhep.2020.05.051|10.1016/S0140-6736(20)31561-0
Personal Author:
Nagarajan, Ramya ; Krishnamoorthy, Yuvaraj ; Rajaa, Sathish ; Hariharan, Vishnu Shankar
Nagarajan, Ramya ; Krishnamoorthy, Yuvaraj ; Rajaa, Sathish ; Hariharan, Vishnu Shankar Less -
Description:
Introduction

Pre-existing comorbid conditions in COVID-19 patients are risk factors for developing severe disease and death. We aimed to determine the association of chronic liver disease (CLD), a comorbid condition, with severity of disease and death among COVID-19 patients.

Methods

We searched for studies reporting COVID-19 outcomes among CLD and non-CLD patients in databases including Medline, EMBASE, ScienceDirect, Google Scholar, and Cochrane Library from inception of the pandemic until February 2022. Risk of bias assessment was conducted by using the Newcastle-Ottawa Scale for assessing the quality of nonrandomized studies in meta-analyses. We conducted a meta-analysis with a random-effects model and reported pooled odds ratios (ORs) with 95% CIs.

Results

We included 40 studies with 908,032 participants. Most studies were conducted in China and the US. COVID-19 patients with CLD had significantly higher odds of having a severe form of COVID-19 (pooled OR = 2.44; 95% CI, 1.89–3.16) and death (pooled OR = 2.35; 95% CI, 1.85–3.00) when compared with COVID-19 patients without CLD.

Conclusion

The presence of CLD is significantly related to adverse clinical outcomes among COVID-19 patients in terms of severity and mortality. Clinicians should develop a comprehensive intervention plan to manage these high-risk patients and reduce COVID-19–related deaths.


Subject:
[+]
Comorbidity COVID-19 Humans Liver Diseases Pandemics Risk Factors
Source:
Prev Chronic Dis. 2022; 19
Pubmed ID:
36007255
Pubmed Central ID:
PMC9480842
Document Type:
Journal Article
Genre:
Systematic Review
Collection(s):
Preventing Chronic Disease
Main Document Checksum:
[+]
urn:sha256:407fe539c9b199697c94c3e2374f6cb2c14099a713d8826989290e1c57e9e9ec
Download URL:
https://stacks.cdc.gov/view/cdc/122181/cdc_122181_DS1.pdf
File Type:

Supporting Files

• 	PCD-19-E53.nxml	xml
  	PCD-19-E53s01.gif	gif
  	PCD-19-E53s01.jpg	jpeg
  	PCD-19-E53s02.gif	gif
  	PCD-19-E53s02.jpg	jpeg
  	PCD-19-E53s03.gif	gif
  	PCD-19-E53s03.jpg	jpeg

More +